Stocktoria

HARROW, INC. HROW

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-02-08 · LEI

HARROW, INC. financials (annual)

Revenue
$19.9M $26.8M $41.4M $51.2M $48.9M $72.5M $88.6M $130.2M $199.6M $272.3M 2016201720182019202020212022202320242025
Net income
-$19.1M -$12.0M $14.6M $168000 -$3.4M -$18.0M -$14.1M -$24.4M -$17.5M -$5.1M 2016201720182019202020212022202320242025
Free cash flow
-$18.1M -$9.6M -$1.1M -$518000 -$2.0M $3.3M -$892000 $2.4M -$23.8M $43.0M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$272.3M$199.6M$130.2M$88.6M$72.5M$48.9M$51.2M$41.4M$26.8M$19.9M
Gross profit$204.4M$150.4M$90.6M$63.2M$54.3M$34.4M$34.4M$24.9M$13.3M$10.1M
R&D expense$20.9M$12.2M$6.7M$3.0M$11.1M$2.4M$2.1M$825,000$413,000$739,000
SG&A expense$152.9M$129.1M$83.1M$58.2M$41.3M$31.2M$33.1M$29.2M$25.0M
Operating income$30.5M$8.8M$431,000$1.9M$1.6M$385,000-$4.8M-$5.2M-$12.2M-$15.9M
Interest expense$21.3M$7.2M$5.4M
Income tax$3.8M$161,000$701,000$75,000$133,000$4,000$8,000-$935,000-$111,000
Net income-$5.1M-$17.5M-$24.4M-$14.1M-$18.0M-$3.4M$168,000$14.6M-$12.0M-$19.1M
EPS (diluted)$-0.14$-0.49$-0.75$-0.51$-0.13$0.01$0.61$-0.60
Operating cash flow$43.9M-$22.2M$3.8M$1.7M$5.1M-$1.1M$950,000$687,000-$8.8M-$11.2M
Free cash flow$43.0M-$23.8M$2.4M-$892,000$3.3M-$2.0M-$518,000-$1.1M-$9.6M-$18.1M
Cash & equivalents$72.9M$47.2M$74.1M$96.3M$42.2M$4.1M$4.7M$4.0M$8.9M
Inventory$13.5M$10.7M$10.9M$6.5M$4.2M$4.0M$3.3M$1.8M$2.2M$1.8M
Total assets$399.5M$389.0M$312.2M$157.4M$98.3M$57.5M$59.1M$49.5M$23.9M$27.2M
Total liabilities$347.4M$319.7M$241.8M$130.1M$87.4M$30.6M$31.7M$24.7M$21.3M$20.8M
Shareholders' equity$52.4M$69.7M$70.8M$27.6M$11.3M$27.2M$27.7M$24.8M$2.6M$6.4M

Growth · year-over-year · Revenue CAGR 33.7%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+36.4%+53.3%+47.0%+22.2%+48.3%-4.5%+23.7%+54.5%+34.3%+105.2%
Net income growth-2098.2%-98.9%
EPS growth-1400.0%-98.4%
Free cash flow growth-1099.9%-127.1%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.